Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment
»
Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment
Glioblastoma is often associated with TP53 mutation, which is associated with a worse prognosis and response to conventional treatment (chemoradiotherapy). Therefore, targeting TP53 is a promising strategy to overcome this poor therapeutic response. The tumor-treating fields (TTFields) is a new treatment recently approved for newly diagnosed glioblastoma multiforme, which involves the direct application of an electric field of low intensity, intermediate frequency back to the tumor, thus offering a tumor-killing effect locally.
However, the effect of TP53 mutation status on the effectiveness of TTFields controversial. Here, we identify the signature key genes and pathways associated with TTFields in four glioblastoma cell lines vary in using gene TP53 mutation status and functional annotation profiles. Overall, the genes associated with cell cycle, cell death, and the immune response is significantly altered by TTFields regardless TP53 status.
TTFields appear to exert enhanced anti-cancer effects by altering the immune system in inflammatory environment and regulate cell cycle- and cell death-related genes, but the right genes are affected varies according to the TP53 status. These results should facilitate detailed mechanistic studies on the molecular basis TTFields to further develop this modality as combination therapy, which can enhance the therapeutic effects and minimize the side effects of chemoradiotherapy.
Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment
Analytical Validation HEARTBiT: A Blood-Based Gene Expression Profiling Multiplex Assay for Diagnosis exclusive Acute Cellular Rejection in Heart Transplant Patients
Background: HEARTBiT is the gene profiles of whole blood-based assay using nucleic acid technology NanoString counting exclusively for the diagnosis of acute cellular rejection in heart transplant patients. Steps score HEARTBiT risk of acute cellular rejection in the first year after heart transplantation, distinguish patients with stable graft of those at risk of acute cellular rejection. Here, we provide performance characteristics HEARTBiT test analysis and results of the pilot clinical validation.
Methods: We used the purified RNA collected from PAXgene blood samples to evaluate the characteristics of the 12-gene assay HEARTBiT panel, for the range of linearity, quantitative bias, precision, and reproducibility. This parameter is expected either from individual samples or a serial dilution of repeated runs on the samples collected. Results: We found that all 12 genes showed a linear behavior in a wide range of recommended test input of 125 ng to 500 ng of purified RNA, with most of the genes that showed 3% or lower quantitative bias and approximately 5% of the variation coefficient. Total variation resulting from a unique operator, many reagents, and walked less than 0.02 units of standard deviation (SD). Validated analytical test performance (AUC = 0.75) is equivalent to what we observe in the development dataset signature.
Conclusion: Performance analysis of the various input specification test indicates a reliable quantification of the HEARTBiT score 0.02 SD units, measured on a scale of 0 to 1 Units. this test because it may be of high utility in the clinical validation of biomarkers HEARTBiT in observational trial period.
Description: Prosapip2 Antibody: Prosapip2 (TBKBP1) is essential for signal transduction during viral infection thus plays a major role in the TNF/NF-κB pathway. It is an adaptor protein that constitutively binds TBK1 (TANK-binding kinase) and IKBKE and may play a role in antiviral innate immunity. Prosapip2 is a 615 amino acid adaptor protein belonging to the fibrillar collagen family, consisting of trimers of identical alpha 1 chains which are linked to each other by interchain disulfide bonds. It has a ubiquitous expression with highest levels in ovary, followed by the neuronal system. Prosapip2 binds to TBK1 and helps in the activation of IRF3 which controls the expression of antiviral genes during infection. Recent studies show that Prosapip2 is an interaction partner of ProSAP2/Shank3 and actin, suggesting a role as a linker molecule between postsynaptic density and the cytoskeleton.
Description: Prosapip2 Antibody: Prosapip2 (TBKBP1) is essential for signal transduction during viral infection thus plays a major role in the TNF/NF-κB pathway. It is an adaptor protein that constitutively binds TBK1 (TANK-binding kinase) and IKBKE and may play a role in antiviral innate immunity. Prosapip2 is a 615 amino acid adaptor protein belonging to the fibrillar collagen family, consisting of trimers of identical alpha 1 chains which are linked to each other by interchain disulfide bonds. It has a ubiquitous expression with highest levels in ovary, followed by the neuronal system. Prosapip2 binds to TBK1 and helps in the activation of IRF3 which controls the expression of antiviral genes during infection. Recent studies show that Prosapip2 is an interaction partner of ProSAP2/Shank3 and actin, suggesting a role as a linker molecule between postsynaptic density and the cytoskeleton.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Prosapip1 . This antibody is tested and proven to work in the following applications:
Description: Prosapip1 Antibody: Prosapip1 is a binding partner of the postsynaptic density (PSD) protein ProSAP2/Shank3, a major scaffolding protein in excitatory brain synapses. Prosapip1 is thought to bind ProSAP2/Shank3 through ProSAP2/Shank3's PDZ domain and link it in turn to the Spine-associated Rap-Gap (SPAR). Prosapip1 shares significant homology with another PSD protein, PSD-Zip70, with both coding for a Fez1 domain that can be found in a total of four related protein, forming a novel family of scaffolding molecules termed ‘Fezzins'. Recent studies show that Prosapip1 can be found in endocrine cells in which it is localized primarily in the hormone-storing compartment of these cells, suggesting that Prosapip1 may have other functions in non-neuronal cells.
Description: Prosapip1 Antibody: Prosapip1 is a binding partner of the postsynaptic density (PSD) protein ProSAP2/Shank3, a major scaffolding protein in excitatory brain synapses. Prosapip1 is thought to bind ProSAP2/Shank3 through ProSAP2/Shank3's PDZ domain and link it in turn to the Spine-associated Rap-Gap (SPAR). Prosapip1 shares significant homology with another PSD protein, PSD-Zip70, with both coding for a Fez1 domain that can be found in a total of four related protein, forming a novel family of scaffolding molecules termed ‘Fezzins'. Recent studies show that Prosapip1 can be found in endocrine cells in which it is localized primarily in the hormone-storing compartment of these cells, suggesting that Prosapip1 may have other functions in non-neuronal cells.
Maladaptive cardiac remodeling is a consequence of pathological hypertrophy including changes in cardiomyocytes and decrease contractility. Studies cardiomyocyte-specific gene expression we express a specific gene program for pathological hypertrophy have been conserved in mice illness and human cardiomyocytes. We identified a new gene PFKP as actively involved in cardiomyocyte remodeling, showed PFKP as a potential therapeutic target to block the progression of heart failure
